Scarica l'app Stockscreener
2.37
1.72%
0.04
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$2.33
Aprire:
$2.3
Volume 24 ore:
71,698
Relative Volume:
0.42
Capitalizzazione di mercato:
$38.04M
Reddito:
$6.66M
Utile/perdita netta:
$-25.52M
Rapporto P/E:
-1.9587
EPS:
-1.21
Flusso di cassa netto:
$-28.98M
1 W Prestazione:
+10.75%
1M Prestazione:
-4.82%
6M Prestazione:
-59.39%
1 anno Prestazione:
-68.16%
Intervallo 1D:
$2.2902
$2.40
Intervallo di 1 settimana:
$2.14
$2.40
Portata 52W:
$2.10
$14.20
Veru Inc Stock (VERU) Company Profile
Nome
Veru Inc
Settore
Industria
Telefono
(312) 595-9123
Indirizzo
2916 N. MIAMI AVENUE, MIAMI, FL
Confronta VERU con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VERU
Veru Inc
|
2.37 | 37.40M | 6.66M | -25.52M | -28.98M | -1.21 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Veru Inc Stock (VERU) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-18 | Iniziato | Canaccord Genuity | Buy |
| 2024-05-14 | Iniziato | B. Riley Securities | Buy |
| 2024-03-28 | Iniziato | Raymond James | Outperform |
| 2023-06-07 | Aggiornamento | Jefferies | Underperform → Hold |
| 2021-04-13 | Iniziato | Jefferies | Buy |
| 2021-02-09 | Reiterato | H.C. Wainwright | Buy |
| 2020-01-21 | Reiterato | H.C. Wainwright | Buy |
| 2019-03-20 | Iniziato | Oppenheimer | Outperform |
| 2018-07-03 | Iniziato | Maxim Group | Buy |
Mostra tutto
Veru Inc Borsa (VERU) Ultime notizie
Is Veru Inc. (FMW) stock prepared for digital transition2026 world cup usa national team round of 32 defensive leaders high defensive line odds analysis analysis - ulpravda.ru
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Veru (NASDAQ:VERU) Share Price Crosses Below Two Hundred Day Moving Average – What’s Next? - Defense World
Veru outlines 72-week Phase IIb PLATEAU study targeting obesity plateau population following FDA guidance - MSN
Veru Inc | 4: Statement of changes in beneficial ownership of securities-Director Hyun Grace - 富途牛牛
Veru Inc. (NASDAQ:VERU) Q4 2025 Earnings Call Transcript - Insider Monkey
Market Review: Can Veru Inc stock maintain growth trajectoryJuly 2025 Short Interest & Trade Opportunity Analysis Reports - moha.gov.vn
Veru Inc. Earnings Call: Lean Mass Wins, Losses Mount - TipRanks
Is Veru Inc. stock a buy in volatile markets2025 Market Outlook & Weekly Watchlist of Top Performers - Улправда
Will Veru Inc. stock outperform Nasdaq indexPortfolio Value Summary & Free Real-Time Market Sentiment Alerts - Улправда
MACD Signal: Why Veru Inc. stock remains resilientTrade Entry Summary & Short-Term High Return Ideas - moha.gov.vn
Veru (NASDAQ:VERU) Upgraded by Wall Street Zen to Hold Rating - Defense World
Will Veru Inc. (FMW) stock profit from fiscal stimulusDividend Hike & Accurate Trade Setup Notifications - Улправда
How Veru Inc. stock reacts to oil pricesMarket Sentiment Summary & Daily Stock Trend Reports - Улправда
Is Veru Inc. stock attractive after correctionPortfolio Update Summary & AI Powered Buy and Sell Recommendations - DonanımHaber
Will Veru Inc. stock continue dividend increasesMarket Risk Report & Technical Confirmation Alerts - Улправда
Canaccord Genuity Initiates Coverage of Veru (VERU) with Buy Recommendation - Nasdaq
Veru Inc. (VERU): Canaccord Genuity Initiates Coverage with a $2 - GuruFocus
Oppenheimer reiterates Outperform rating on Veru stock as enobosarm advances By Investing.com - Investing.com Nigeria
Oppenheimer reiterates Outperform rating on Veru stock as enobosarm advances - Investing.com Nigeria
Veru shares clinical progress in obesity program, details 2025 results By Investing.com - Investing.com Nigeria
Veru Inc (VERU) Q4 2025 Earnings Call Highlights: Strategic Shifts and Financial Challenges By GuruFocus - Investing.com Canada
Veru Inc (VERU) Q4 2025 Earnings Call Highlights: Strategic Shifts and Financial Challenges - Yahoo Finance
Veru Q4 2025 Earnings Call Transcript - MarketBeat
Veru Inc. (VERU) Q4 2025 Earnings Call Transcript Summary - 富途牛牛
Veru Inc. (VERU) Releases Q4 2025 Earnings: Flat Revenue, EPS Beat Amid Profitability and Cash Pressure - Quiver Quantitative
VERU INC. SEC 10-K Report - TradingView — Track All Markets
VERU: Net loss of $22.7M in FY2025, no commercial revenue, and urgent need for new capital - TradingView — Track All Markets
Earnings call transcript: Veru Inc. Q4 2025 sees strategic shifts amid financial losses - Investing.com India
Veru Inc. Reports Earnings Results for the Full Year Ended September 30, 2025 - marketscreener.com
Veru shares clinical progress in obesity program, details 2025 results - Investing.com
Veru Inc. Reports Fiscal Year 2025 Financial Results and Clinical Program Progress - TradingView — Track All Markets
Veru Inc. (NASDAQ: VERU) furnishes press release with FY 2025 results - Stock Titan
Veru (VERU) Beats EPS Expectations Despite Cash Decline - GuruFocus
Veru Inc. Achieves FDA Regulatory Clarity for Enobosarm as a Combination Therapy for Obesity Following Positive Phase 2b Study Results - Quiver Quantitative
Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress - The Manila Times
Veru Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
A Look Ahead: Veru's Earnings Forecast - Sahm
Top Wall Street Forecasters Revamp Veru Expectations Ahead Of Q4 Earnings - Benzinga
VERU Earnings Preview: Recent $VERU Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Veru Inc. to Host Conference Call for Fiscal Year 2025 Financial Results and Business Update - Quiver Quantitative
Veru to Report Fiscal Year 2025 Financial Results on December 17th - marketscreener.com
Veru targets Phase 3 enobosarm trials following promising Phase 2b results in obesity treatment - MSN
Veru (VERU) to Release Quarterly Earnings on Monday - Defense World
Is Gannett Co Inc 2N2A stock a top hedge fund pickJuly 2025 Final Week & Reliable Entry Point Trade Alerts - BỘ NỘI VỤ
Veru's Upcoming Conference Presentations Draw Investor Scrutiny () - aktiencheck.de
Will Veru Inc. (FMW) stock see valuation expansionJuly 2025 PostEarnings & AI Driven Stock Price Forecasts - Newser
Cash from financing activities of Veru Inc – MUN:FMW0 - TradingView
VERU FinancialsIncome Statement - Quiver Quantitative
Veru Inc. to Highlight Innovative Therapeutics for Obesity Treatment at SCWD 18th International Conference in Rome - Quiver Quantitative
Veru to Present at The Society on Sarcopenia, Cachexia, and Wasting Disorders 18th International Conference and Regulatory and Clinical Trials Update Regulatory Workshop - marketscreener.com
Veru Inc Azioni (VERU) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
28.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):